Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper
Nicolò Matteo Luca Battisti, Nienke A. de Glas, Mina S. Sedrak, et al.
Therapeutic Advances in Medical Oncology (2018) Vol. 10
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG)
Laura Biganzoli, Nicolò Matteo Luca Battisti, Hans Wildiers, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 7, pp. e327-e340
Open Access | Times Cited: 216
Outcomes of Older Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis
Lynn Howie, Harpreet Singh, Erik Bloomquist, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 36, pp. 3475-3483
Open Access | Times Cited: 76
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
Matthew P. Goetz, Meena Okera, Hans Wildiers, et al.
Breast Cancer Research and Treatment (2021) Vol. 186, Iss. 2, pp. 417-428
Open Access | Times Cited: 41
Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review
Vincenzo Di Lauro, Giacomo Barchiesi, Federica Martorana, et al.
ESMO Open (2022) Vol. 7, Iss. 6, pp. 100629-100629
Open Access | Times Cited: 31
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review
Étienne Brain, Connie Chen, Sofia Simon, et al.
Targeted Oncology (2024) Vol. 19, Iss. 3, pp. 303-320
Open Access | Times Cited: 6
Anticancer drugs are not well tolerated in all older patients with cancer
Hans Wildiers, Nienke A. de Glas
The Lancet Healthy Longevity (2020) Vol. 1, Iss. 1, pp. e43-e47
Open Access | Times Cited: 40
Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer
Joosje C. Baltussen, Simon P. Mooijaart, Annelie Vulink, et al.
Breast Cancer Research and Treatment (2024) Vol. 206, Iss. 2, pp. 337-346
Open Access | Times Cited: 4
Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy
Thomas N. O’Connor, Emily Schultz, Jianxin Wang, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1749-1749
Open Access | Times Cited: 4
The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know?
Alexandre Giraudo, Renaud Sabatier, Frédérique Rousseau, et al.
Cancers (2024) Vol. 16, Iss. 10, pp. 1838-1838
Open Access | Times Cited: 4
CDK4/6 as a Therapeutic Target in HR+/HER2− Breast Cancer Cells—Current Treatment Status
Katherine Krupa, Anna Liszcz-Tymoszuk, Natalia Czerw, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 1039-1039
Open Access
The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis
Fausto Petrelli, Lorenzo Dottorini, Giandomenico Di Menna, et al.
The Breast (2023) Vol. 71, pp. 138-142
Open Access | Times Cited: 10
Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review)
M. Teomete, Devrim Çabuk, Taner Korkmaz, et al.
Oncology Letters (2024) Vol. 27, Iss. 4
Open Access | Times Cited: 3
Real-world experience with CDK4-6 inhibition in the old and oldest old with a diagnosis of breast cancer
Paula Sobrini Morillo, Christine Ravot, Chloé Herledan, et al.
Seminars in Oncology (2024) Vol. 51, Iss. 3-4, pp. 95-105
Closed Access | Times Cited: 3
Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study
S. El Badri, Bilal Tahir, K. Balachandran, et al.
The Breast (2021) Vol. 60, pp. 199-205
Open Access | Times Cited: 20
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program
Carlo Palmieri, A. E. Musson, Catherine Harper‐Wynne, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 5, pp. 852-860
Open Access | Times Cited: 8
Cardiovascular complications of ribociclib in breast cancer patients
Oraianthi Fiste, Evangelos Mavrothalassitis, Kleoniki Apostolidou, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104296-104296
Closed Access | Times Cited: 2
Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study
F. Borges, Filipa Alves da Costa, Adriana Ramos, et al.
The Breast (2022) Vol. 62, pp. 135-143
Open Access | Times Cited: 12
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience
Nicolò Matteo Luca Battisti, Belinda Kingston, Judy King, et al.
Breast Cancer Research and Treatment (2019) Vol. 174, Iss. 3, pp. 731-740
Closed Access | Times Cited: 19
SIOG guidelines- essential for good clinical practice in geriatric oncology
Roman Dubiański, Tanya M. Wildes, Hans Wildiers
Journal of Geriatric Oncology (2019) Vol. 10, Iss. 2, pp. 196-198
Open Access | Times Cited: 13
Targeted therapy for breast cancer in older patients
Noam Pondé, Hans Wildiers, Ahmad Awada, et al.
Journal of Geriatric Oncology (2019) Vol. 11, Iss. 3, pp. 380-388
Open Access | Times Cited: 12
Real-world effectiveness of aromatase inhibitors and fulvestrant in HR+/HER2- advanced breast cancer: a snapshot of the last two years before conventional use of CDK 4/6 inhibitors in a Portuguese institution
Maria Inês Teodoro, Alexandra Mayer, Ana da Costa Miranda, et al.
Journal of Pharmaceutical Policy and Practice (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Breast Cancer
Gretell Henríquez, Nicolò Matteo Luca Battisti, Yanin Chávarri-Guerra, et al.
Geriatric medicine (2024), pp. 827-854
Closed Access | Times Cited: 1
Systemic therapy for older patients with early breast cancer
Nicolò Matteo Luca Battisti, Kroopa Joshi, Mariam Syeda Nasser, et al.
Cancer Treatment Reviews (2021) Vol. 100, pp. 102292-102292
Closed Access | Times Cited: 10
Is adjuvant chemotherapy necessary in older patients with breast cancer?
Midori Morita, Akihiko Shimomura, Emi Tokuda, et al.
Breast Cancer (2022) Vol. 29, Iss. 3, pp. 498-506
Open Access | Times Cited: 7
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
Javier Salvador Bofill, Fernando Moreno Antón, César A. Rodríguez, et al.
The Breast (2022) Vol. 66, pp. 77-84
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top